Literature DB >> 32289395

Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review.

Ajay N Sharma1, Natasha A Mesinkovska1, Taraneh Paravar2.   

Abstract

BACKGROUND: Hydroxychloroquine is associated with myriad adverse dermatologic effects, most of which are poorly characterized by the literature, with unknown frequencies and risk factors.
OBJECTIVE: To conduct a systematic review of the adverse dermatologic effects and predisposing factors of hydroxychloroquine toxicity.
RESULTS: The review included 94 articles comprising 689 dermatologic adverse effects. A total of 21 unique dermatologic reactions were reported, most commonly drug eruption or rash (358 cases), cutaneous hyperpigmentation (116), pruritus (62), acute generalized exanthematous pustulosis (27), Stevens-Johnson syndrome or toxic epidermal necrolysis (26), hair loss (12), and stomatitis (11). Almost all underlying conditions were rheumatologic or autoimmune in nature, composed primarily of lupus erythematous (72% of all cases) and rheumatoid arthritis (14%). The range of reported mean cumulative dosages was wide, with some adverse reactions found after as little as 3 g or as much as 2500 g. LIMITATIONS: Dermatologic adverse events and primary diagnoses related to the use of hydroxychloroquine may be under-reported as only case reports and clinical trials that reported at least 1 dermatologic adverse effect were included.
CONCLUSION: Although hydroxychloroquine is generally well tolerated, dermatologic adverse effects involving the skin, hair, or nails are a frequent and significant complication. Most of these reactions occurred after treatment of autoimmune conditions, often manifesting on the skin after a wide range of cumulative dosages.
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Plaquenil; adverse effect; adverse event; antimalarial; autoimmune; dermatomyositis; drug eruption; drug rash; hydroxychloroquine; hyperpigmentation; lupus; rheumatology

Mesh:

Substances:

Year:  2020        PMID: 32289395     DOI: 10.1016/j.jaad.2020.04.024

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  27 in total

1.  Cutaneous Manifestations of COVID-19: A Systematic Review.

Authors:  Harjas Singh; Harleen Kaur; Kanhaiya Singh; Chandan K Sen
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-10-19       Impact factor: 4.730

2.  Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.

Authors:  Atiya R Faruqui; Denis Xavier; Sandhya K Kamat; Sujith J Chandy; Bikash Medhi; Raakhi K Tripathi; Yashashri C Shetty; John Michael Raj; Sandeep Kaushal; S Balakrishnan; Shubham Atal; Santanu K Tripathi; Dinesh K Badyal; Harihar Dikshit; Sukalyan Saha Roy; Niyati Trivedi; Suparna Chatterjee; Chetna Desai; C D Tripathi; Nirmala N Rege; Pooja Gupta; R Raveendran; Rajni Kaul; Nilima A Kshirsagar
Journal:  Indian J Med Res       Date:  2021 Jan & Feb       Impact factor: 2.375

3.  Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.

Authors:  Işın Nur Sultan Öncü; Dilara Güler; Gülhan Gürel
Journal:  Dermatol Ther       Date:  2021-02-24       Impact factor: 3.858

4.  Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.

Authors:  Noureddine Litaiem; Khaoula Hajlaoui; Manel Karray; Maroua Slouma; Faten Zeglaoui
Journal:  Dermatol Ther       Date:  2020-05-26       Impact factor: 2.851

5.  Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration.

Authors:  Shari R Lipner; Yu Wang
Journal:  J Am Acad Dermatol       Date:  2020-07-08       Impact factor: 11.527

6.  Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.

Authors:  Jérémie Delaleu; Benjamin Deniau; Maxime Battistella; Adèle de Masson; Benoit Bensaid; Marie Jachiet; Ingrid Lazaridou; Martine Bagot; Jean-David Bouaziz
Journal:  J Allergy Clin Immunol Pract       Date:  2020-06-07

7.  Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.

Authors:  Tyler Enos; Haneol S Jeong; Travis Vandergriff; Heidi T Jacobe; Benjamin F Chong
Journal:  Dermatol Ther       Date:  2020-07-08       Impact factor: 3.858

Review 8.  Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review.

Authors:  Niloufar Najar Nobari; Azadeh Goodarzi
Journal:  Dermatol Ther       Date:  2020-07-07       Impact factor: 3.858

9.  Novel case of an adult with toxic shock syndrome following COVID-19 infection.

Authors:  Yilin Feng; Stephen T Armenti; Owen R Albin; Shahzad I Mian
Journal:  Am J Ophthalmol Case Rep       Date:  2020-07-29

Review 10.  Treatment of COVID 19-Repurposing drugs commonly used in dermatology.

Authors:  Jelena Stojkovic-Filipovic; Martina Bosic
Journal:  Dermatol Ther       Date:  2020-07-16       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.